Literature DB >> 20841546

A global rank end point for clinical trials in acute heart failure.

G Michael Felker1, Alan S Maisel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20841546     DOI： 10.1161/CIRCHEARTFAILURE.109.926030

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN： 1941-3289            Impact factor:   8.790


× No keyword cloud information.
  24 in total

1.  Overcoming underpowering: Trial simulations and a global rank end point to optimize clinical trials in children with heart disease.

Authors:  Kevin D Hill; H Scott Baldwin; David P Bichel; Alicia M Ellis; Eric M Graham; Christoph P Hornik; Jeffrey P Jacobs; Robert D B Jaquiss; Marshall L Jacobs; Prince J Kannankeril; Jennifer S Li; Rachel Torok; Joseph W Turek; Sean M O'Brien
Journal:  Am Heart J       Date:  2020-05-20       Impact factor: 4.749

2.  Power and sample size calculations for the Wilcoxon-Mann-Whitney test in the presence of death-censored observations.

Authors:  Roland A Matsouaka; Rebecca A Betensky
Journal:  Stat Med       Date:  2014-11-13       Impact factor: 2.373

Review 3.  Paediatric cardiovascular clinical trials: an analysis of ClinicalTrials.gov and the Food and Drug Administration Pediatric Drug Labeling Database.

Authors:  Kevin D Hill; Heather T Henderson; Christoph P Hornik; Jennifer S Li
Journal:  Cardiol Young       Date:  2015-08       Impact factor: 1.093

Review 4.  Novel therapeutic targets for the treatment of heart failure.

Authors:  Juan Tamargo; José López-Sendón
Journal:  Nat Rev Drug Discov       Date:  2011-06-24       Impact factor: 84.694

5.  An optimal Wilcoxon-Mann-Whitney test of mortality and a continuous outcome.

Authors:  Roland A Matsouaka; Aneesh B Singhal; Rebecca A Betensky
Journal:  Stat Methods Med Res       Date:  2016-12-29       Impact factor: 3.021

6.  Effects of Coping Skills Training on Quality of Life, Disease Biomarkers, and Clinical Outcomes in Patients With Heart Failure: A Randomized Clinical Trial.

Authors:  Andrew Sherwood; James A Blumenthal; Gary G Koch; Benson M Hoffman; Lana L Watkins; Patrick J Smith; Christopher M O'Connor; Kirkwood F Adams; Joseph G Rogers; Carla Sueta; Patricia P Chang; Kristy S Johnson; Jeanne Schwartz; Alan L Hinderliter
Journal:  Circ Heart Fail       Date:  2017-01       Impact factor: 8.790

7.  Rethinking Phase II Clinical Trial Design in Heart Failure.

Authors:  Kory J Lavine; Douglas L Mann
Journal:  Clin Investig (Lond)       Date:  2013-01-01

8.  Atypical Skeletal Muscle Profiles in Human Immunodeficiency Virus-Infected Asymptomatic Middle-Aged Adults.

Authors:  Thanh Tran; Viola Guardigni; Karol M Pencina; Anthony A Amato; Michael Floyd; Brooke Brawley; Brian Mozeleski; Jennifer McKinnon; Erin Woodbury; Emily Heckel; Zhuoying Li; Tom Storer; Paul E Sax; Monty Montano
Journal:  Clin Infect Dis       Date:  2018-06-01       Impact factor: 9.079

Review 9.  Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations.

Authors:  Muthiah Vaduganathan; Javed Butler; Lothar Roessig; Gregg C Fonarow; Stephen J Greene; Marco Metra; Gadi Cotter; Stuart Kupfer; Andrew Zalewski; Naoki Sato; Gerasimos Filippatos; Mihai Gheorghiade
Journal:  Heart Fail Rev       Date:  2015-07       Impact factor: 4.214

Review 10.  Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure.

Authors:  Stephen J Greene; Robert J Mentz; Mona Fiuzat; Javed Butler; Scott D Solomon; Andrew P Ambrosy; Cyrus Mehta; John R Teerlink; Faiez Zannad; Christopher M O'Connor
Journal:  Circulation       Date:  2018-09-04       Impact factor: 29.690
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.